Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Dose Optimization Study of Platinum/Etoposide Plus Ivonescimab (CEI) as First-Line Treatment of Extensive-Stage Small Cell Lung Cancer

NCT07057791 is registered in ClinicalTrials.gov with PrECOG, LLC. as lead sponsor.

NCT NCT07057791
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07057791 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Dose Optimization Study of Platinum/Etoposide Plus Ivonescimab (CEI) as First-Line Treatment of Extensive-Stage Small Cell Lung Cancer
Lead sponsor
PrECOG, LLC.
Phase
Phase 2
Overall status
Recruiting
Start date
March 30, 2026
Completion date
January 31, 2030
Enrollment
60 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

extensive stage lung small cell cancer